CHÉOS Director Dr. Aslam Anis, with fellow scientists Drs. Carlo Marra and Larry Lynd, have received a two-year operating grant through the Canadian Institutes of Health Research (CIHR) for their research project, “The impact of price-caps on the generic pharmaceutical industry and provincial drug plan costs in Canada.”
Here is an excerpt from their abstract:
“Since 2010, several provincial governments in Canada have announced reductions in the maximum price of generic drugs, setting new price caps as a percentage of the price of the branded drug product. Despite their popularity, evidence suggests that price caps may result in higher priced generics than would exist without regulation, and may even inhibit new generic drugs from entering the market.
“The objectives of this study are to examine the influence of different price caps on market entry of new generic drugs and assess the impact of different price caps on generic drug prices across Canada.”
Dr. Lynd and his team have also received an emerging team grant from CIHR in the category of Rare Diseases – Health Services. This five-year grant will allow Dr. Lynd to pursue his project, titled, “Developing a Canadian framework for evaluation and decision-making for expensive drugs for rare diseases through innovation, value and priority setting.” Here is an excerpt from the abstract:
“As our understanding of diseases and how to treat them evolves, so too must our decision-making procedures for providing fair and cost-effective treatments for those living with an illness.
“At present, there is no policy framework to help decision makers navigate the complex factors involved when making decisions about paying for orphan drugs. This project brings together a multidisciplinary team of experts in matters relating to treatment for rare diseases, and will incorporate input from the public and key stakeholders to develop such a framework.”